Mena FN

Antengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma'

- XPOVIO®, in combination with bortezomib and dexamethasone (XBd), gives patients with relapsed and/or refractory multiple myeloma, a new treatment option. - XPOVIO®, in combination with dexamethasone ...
Pharmabiz

Antengene’s Xpovio gets Australian TGA approval to treat R/R MM & triple class-refractory multiple myeloma

Antengene Corporation Limited (Antengene), a leading innovative commercial stage global biopharmaceutical company, announced that the Therapeutic Goods Administration (TGA) of the Australian ...